JP2023521663A5 - - Google Patents
Info
- Publication number
- JP2023521663A5 JP2023521663A5 JP2022560227A JP2022560227A JP2023521663A5 JP 2023521663 A5 JP2023521663 A5 JP 2023521663A5 JP 2022560227 A JP2022560227 A JP 2022560227A JP 2022560227 A JP2022560227 A JP 2022560227A JP 2023521663 A5 JP2023521663 A5 JP 2023521663A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- cells
- approximately
- biologically active
- targeted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025197130A JP2026067851A (ja) | 2020-03-31 | 2025-11-18 | 標的化脂質粒子及び組成物ならびにその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003168P | 2020-03-31 | 2020-03-31 | |
| US63/003,168 | 2020-03-31 | ||
| US202163154341P | 2021-02-26 | 2021-02-26 | |
| US63/154,341 | 2021-02-26 | ||
| PCT/US2021/024993 WO2021202604A1 (en) | 2020-03-31 | 2021-03-30 | Targeted lipid particles and compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025197130A Division JP2026067851A (ja) | 2020-03-31 | 2025-11-18 | 標的化脂質粒子及び組成物ならびにその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023521663A JP2023521663A (ja) | 2023-05-25 |
| JP2023521663A5 true JP2023521663A5 (enExample) | 2024-04-10 |
Family
ID=75639978
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022560227A Pending JP2023521663A (ja) | 2020-03-31 | 2021-03-30 | 標的化脂質粒子及び組成物ならびにその使用 |
| JP2025197130A Pending JP2026067851A (ja) | 2020-03-31 | 2025-11-18 | 標的化脂質粒子及び組成物ならびにその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025197130A Pending JP2026067851A (ja) | 2020-03-31 | 2025-11-18 | 標的化脂質粒子及び組成物ならびにその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210353543A1 (enExample) |
| EP (1) | EP4127144A1 (enExample) |
| JP (2) | JP2023521663A (enExample) |
| KR (1) | KR20230006819A (enExample) |
| CN (1) | CN116096866A (enExample) |
| AU (1) | AU2021248815A1 (enExample) |
| CA (1) | CA3178308A1 (enExample) |
| IL (1) | IL296621A (enExample) |
| MX (1) | MX2022012191A (enExample) |
| WO (1) | WO2021202604A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| WO2020191233A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2020252455A1 (en) | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| CA3189601A1 (en) | 2020-07-24 | 2022-01-27 | The General Hospital Corporation | Enhanced virus-like particles and methods of use thereof for delivery to cells |
| KR20240028975A (ko) * | 2021-04-08 | 2024-03-05 | 사나 바이오테크놀로지, 인크. | Cd8-특이적 항체 구조체들 및 이의 조성물 |
| WO2022261149A2 (en) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Particle delivery systems |
| EP4463135A2 (en) * | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023150647A1 (en) * | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2024081936A1 (en) * | 2022-10-13 | 2024-04-18 | Northwestern University | Methods for assembling protein-conjugated nanocarrier vaccines |
| WO2024119157A1 (en) * | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| US20240293462A1 (en) * | 2023-03-03 | 2024-09-05 | Trustees Of Boston University | Immune Cell Fusion (ICF) and Uses Thereof |
| EP4698666A1 (en) * | 2023-04-18 | 2026-02-25 | Sana Biotechnology, Inc. | Universal protein g fusogens and adapter systems thereof and related lipid particles and uses |
| WO2024220560A1 (en) * | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Engineered protein g fusogens and related lipid particles and methods thereof |
| WO2024254544A2 (en) * | 2023-06-07 | 2024-12-12 | Nvelop Therapeutics, Inc. | Compositions and methods for promoting payload delivery in cells |
| WO2025085950A1 (en) * | 2023-10-27 | 2025-05-01 | Monash University | Compositions and methods for targeting lipid nanoparticles |
| CN120505421B (zh) * | 2025-07-18 | 2025-09-23 | 宁波大学附属第一医院 | 一种用于辅助诊断结直肠癌的eRNA分子标记物及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| PT904392E (pt) | 1996-10-17 | 2001-06-29 | Oxford Biomedica Ltd | Vectores retrovirais |
| GB9720465D0 (en) | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| ES2373406T3 (es) | 1997-12-22 | 2012-02-03 | Oxford Biomedica (Uk) Limited | Vectores basados en el virus de la anemia infecciosa equina (vaie). |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| US9085778B2 (en) | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CN103946952A (zh) | 2011-09-16 | 2014-07-23 | 宾夕法尼亚大学董事会 | 用于治疗癌症的rna改造的t细胞 |
| EP2844746A4 (en) | 2012-03-26 | 2016-07-20 | Univ California | PSEUDOTYPIZED LENTIVIRES WITH NIPAH VIRUS COVERS AND METHOD OF USE THEREOF |
| CN105051192B (zh) | 2012-11-13 | 2020-04-17 | 科迪艾克生物科学公司 | 治疗剂的递送 |
| EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| WO2016077639A2 (en) | 2014-11-12 | 2016-05-19 | VL27, Inc. | Nanovesicular therapies |
| CA3017586A1 (en) | 2016-03-15 | 2017-09-21 | Codiak Biosciences, Inc. | Therapeutic membrane vesicles |
| EP3235908A1 (en) * | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| WO2018115507A2 (en) * | 2016-12-23 | 2018-06-28 | Curevac Ag | Henipavirus vaccine |
| CA3062426A1 (en) * | 2017-05-08 | 2018-11-15 | Flagship Pioneering Innovations V, Inc. | Compositions for facilitating membrane fusion and uses thereof |
| KR102758204B1 (ko) * | 2017-10-30 | 2025-01-23 | 밀테니 비오텍 비.브이. & 씨오. 케이지 | 표적 세포의 선택적 형질도입을 위한 어댑터-기반 레트로바이러스 벡터 시스템 |
| SG11202011015QA (en) * | 2018-05-15 | 2020-12-30 | Flagship Pioneering Innovations V Inc | Fusosome compositions and uses thereof |
| CN112955174A (zh) * | 2018-07-09 | 2021-06-11 | 旗舰先锋创新V股份有限公司 | 融合剂脂质体组合物和其用途 |
| US20220008557A1 (en) * | 2018-11-14 | 2022-01-13 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for cns delivery |
| AU2019378883A1 (en) * | 2018-11-14 | 2021-06-03 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for T cell delivery |
-
2021
- 2021-03-30 CA CA3178308A patent/CA3178308A1/en active Pending
- 2021-03-30 JP JP2022560227A patent/JP2023521663A/ja active Pending
- 2021-03-30 MX MX2022012191A patent/MX2022012191A/es unknown
- 2021-03-30 IL IL296621A patent/IL296621A/en unknown
- 2021-03-30 CN CN202180038773.7A patent/CN116096866A/zh active Pending
- 2021-03-30 KR KR1020227037815A patent/KR20230006819A/ko active Pending
- 2021-03-30 WO PCT/US2021/024993 patent/WO2021202604A1/en not_active Ceased
- 2021-03-30 US US17/218,025 patent/US20210353543A1/en active Pending
- 2021-03-30 EP EP21720890.9A patent/EP4127144A1/en active Pending
- 2021-03-30 AU AU2021248815A patent/AU2021248815A1/en active Pending
-
2025
- 2025-11-18 JP JP2025197130A patent/JP2026067851A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023521663A5 (enExample) | ||
| JP7474281B2 (ja) | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 | |
| JP6664528B2 (ja) | Ｃｌｄ１８ａ２標的免疫エフェクター細胞及びその調製方法と使用 | |
| JP5553989B2 (ja) | ウィルスベクターを使用した標的化遺伝子送達方法 | |
| KR102758204B1 (ko) | 표적 세포의 선택적 형질도입을 위한 어댑터-기반 레트로바이러스 벡터 시스템 | |
| TWI871269B (zh) | 非複製勝任型重組反轉錄病毒顆粒 | |
| CN108350462B (zh) | 嵌合抗原受体及其用途 | |
| JP2019150066A5 (enExample) | ||
| RS62733B1 (sr) | Mnd promoter himernih antigenskih receptora | |
| CN107708710A (zh) | Smart CAR装置,DE CAR多肽,Side CAR及其使用 | |
| JP2021525534A5 (enExample) | ||
| EP3458481A1 (en) | Targeting pd-l1 on tumor cells | |
| CN109336980B (zh) | 一种靶向Muc1的嵌合抗原受体修饰T细胞及其用途 | |
| US20240277769A1 (en) | Preparation and application of chimeric antigen receptor immune cell constructed on basis of lox1 | |
| CN117467705A (zh) | 一种高效的BaEV囊膜病毒包装方法 | |
| WO1998047916A9 (en) | Bifunctional polypeptides for cell-specific viral targeting | |
| JP2026504894A (ja) | 変異型ｐｄ１細胞外ドメインの断片及び当該断片を含むｃａｒとｎｋ細胞 | |
| WO2024022147A1 (zh) | BaEV囊膜糖蛋白及其应用 | |
| WO2023086517A1 (en) | Chimeric antigen receptors | |
| EP4357369A1 (en) | Preparation and application of chimeric antigen receptor immune cell constructed on basis of granzyme b | |
| WO2024220598A2 (en) | Lentiviral vectors with two or more genomes | |
| EP4698665A1 (en) | Engineered protein g fusogens and related lipid particles and methods thereof | |
| CN117467706A (zh) | BaEV囊膜糖蛋白及其应用 | |
| EP4698666A1 (en) | Universal protein g fusogens and adapter systems thereof and related lipid particles and uses | |
| CN115850490A (zh) | 靶向间皮素的纳米抗体、嵌合抗原受体及其应用 |